Overview
- The U.S. Food and Drug Administration approved bemotrizinol for over‑the‑counter sunscreen use on June 9, 2026, marking the first new active ingredient cleared in the United States since 1999.
- Bemotrizinol blocks both UVA and UVB radiation and is highly photostable, with regulatory and scientific summaries noting it can sustain protection for multiple hours rather than degrading quickly in sunlight.
- Regulators classified the ingredient as generally recognized as safe and effective for people six months and older, and published data plus decades of use abroad show it is a large molecule with low skin absorption and no evidence of meaningful systemic accumulation.
- U.S. manufacturers may begin incorporating bemotrizinol into products on Aug. 9, 2026, and shoppers can expect new formulations on shelves later in 2026 as companies complete reformulation, testing and labeling.
- The approval reflects a shift in U.S. sunscreen regulation toward using international data and modern review pathways and could lead to lighter, less greasy sunscreens that increase real‑world use and strengthen skin‑cancer prevention efforts.